Payment overview · 2025
General Payments
$379.82
19 reported records · 13 companies
Healthcare provider profile · identity verified
John Robert Markeson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRIGHAM CITY, UT · NPI 1861503419
Verified facts
What the public records show
CMS Open Payments records show John Robert Markeson, M.D. received $379.82 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.40 | 14.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.08 | 12.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.00 | 9.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.50 | 9.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.04 | 9.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.88 | 8.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.40 | 6.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.74 | 6.2% | 1 | 2025 |
| bioMerieux Inc | Unresolved — no canonical attribution shown | $23.00 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.47 | 5.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.35 | 5.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.20 | 5.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.76 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $379.82 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.31 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 348 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
348 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 140 |
| Prednisone | Prednisone | 450 | 217 |
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 393 | 121 |
| Simvastatin | Simvastatin | 351 | 103 |
| Mounjaro | Tirzepatide | 348 | 58 |
| Omeprazole | Omeprazole | 346 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 319 | 103 |
| Furosemide | Furosemide | 312 | 105 |
| Potassium Chloride | Potassium Chloride | 294 | 104 |
| Losartan Potassium | Losartan Potassium | 290 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 258 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 248 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 124 |
| Lisinopril | Lisinopril | 232 | 76 |
| Metformin Hcl | Metformin Hcl | 231 | 75 |
| Citalopram Hbr | Citalopram Hydrobromide | 223 | 67 |
| Trazodone Hcl | Trazodone Hcl | 222 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 213 | 33 |
| Azithromycin | Azithromycin | 210 | 145 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 194 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 194 | 64 |
| Finasteride | Finasteride | 178 | 58 |
| Glimepiride | Glimepiride | 177 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 56 |
| Gabapentin | Gabapentin | 155 | 50 |
| Celecoxib | Celecoxib | 153 | 74 |
| Eliquis | Apixaban | 153 | 34 |
| Allopurinol | Allopurinol | 142 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 131 | 81 |
| Warfarin Sodium | Warfarin Sodium | 128 | 38 |
| Sertraline Hcl | Sertraline Hcl | 124 | 43 |
| Carvedilol | Carvedilol | 121 | 35 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 117 | 66 |
| Jardiance | Empagliflozin | 117 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 35 |
| Tramadol Hcl | Tramadol Hcl | 110 | 26 |
| Clonazepam | Clonazepam | 100 | 15 |
| Cephalexin | Cephalexin | 96 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 30 |
| Estradiol | Estradiol | 88 | 31 |
| Meloxicam | Meloxicam | 86 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 23 |
| Ibuprofen | Ibuprofen | 80 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 23 |
| Ozempic | Semaglutide | 73 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 51 |
| Temazepam | Temazepam | 63 | suppressed |
| Lorazepam | Lorazepam | 58 | 11 |
| Alprazolam | Alprazolam | 57 | 21 |
| Levofloxacin | Levofloxacin | 56 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 14 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 48 | 19 |
| Farxiga | Dapagliflozin Propanediol | 47 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 16 |
| Xarelto | Rivaroxaban | 45 | 14 |
| Alendronate Sodium | Alendronate Sodium | 44 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 13 |
| Fenofibrate | Fenofibrate | 44 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 25 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 12 |
| Cefdinir | Cefdinir | 37 | 16 |
| Diazepam | Diazepam | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 19 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | 15 |
| Ramipril | Ramipril | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Lansoprazole | Lansoprazole | 32 | 11 |
| Klor-Con M20 | Potassium Chloride | 31 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 11 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 12 |
| Nystatin | Nystatin | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 16 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | 11 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 13 |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 11 |
| Lactulose | Lactulose | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 14 |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Prevalite | Cholestyramine | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $379.82 · 19 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, FREESTYLE LIBRE 3, INSPIRE, JOURNAVX, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error